Eupraxia Pharmaceuticals Quote - EPRX

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

3.11

Bid

1.25

Ask

3.12

Volume

0.00 Day's Range 0.00

2.20 52 Week Range 4.08

Market Cap

110.786M

Previous Close

3.11

Open

Last Trade

3.25

Last Trade Time

06:27:55

Financial Volume

VWAP

Average Volume (3m)

18,261

Shares Outstanding

35,622,553

Dividend Yield

PE Ratio

-5.67

Earnings Per Share (EPS)

-0.79

Revenue

Net Profit

-28.22M

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient be... Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.eupraxiapharma.com

Headquarters

Victoria, British Columbia, Can

Founded

Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was US$3.11. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of US$ 2.20 to US$ 4.08.

Eupraxia Pharmaceuticals currently has 35,622,553 shares outstanding. The market capitalization of Eupraxia Pharmaceuticals is US$110.79 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.67.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire VICTORIA, BC, Nov. 12, 2024...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.01	-0.320512820513	3.12	3.25	2.76	6006	3.02522021	CS
4	-0.49	-13.6111111111	3.6	3.63	2.76	10941	3.26367215	CS
12	0.3675	13.4001823154	2.7425	4.08	2.2	18261	3.1902336	CS
26	0.5	19.1570881226	2.61	4.08	2.2	12274	3.02457409	CS
52	-0.44	-12.3943661972	3.55	4.08	2.2	16312	2.94415018	CS
156	-0.44	-12.3943661972	3.55	4.08	2.2	16312	2.94415018	CS
260	-0.44	-12.3943661972	3.55	4.08	2.2	16312	2.94415018	CS

EPRX - Frequently Asked Questions (FAQ)

What is the current Eupraxia Pharmaceuticals share price?

The current share price of Eupraxia Pharmaceuticals is US$ 3.11

How many Eupraxia Pharmaceuticals shares are in issue?

Eupraxia Pharmaceuticals has 35,622,553 shares in issue

What is the market cap of Eupraxia Pharmaceuticals?

The market capitalisation of Eupraxia Pharmaceuticals is USD 110.79M

What is the 1 year trading range for Eupraxia Pharmaceuticals share price?

Eupraxia Pharmaceuticals has traded in the range of US$ 2.20 to US$ 4.08 during the past year

What is the PE ratio of Eupraxia Pharmaceuticals?

The price to earnings ratio of Eupraxia Pharmaceuticals is -5.67

What is the reporting currency for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals reports financial results in USD

What is the latest annual profit for Eupraxia Pharmaceuticals?

The latest annual profit of Eupraxia Pharmaceuticals is USD -28.22M

What is the registered address of Eupraxia Pharmaceuticals?

The registered address for Eupraxia Pharmaceuticals is 201 - 2067 CADBORO BAY ROAD, VICTORIA, BRITISH COLUMBIA, V8R 5G4.

What is the Eupraxia Pharmaceuticals website address?

The website address for Eupraxia Pharmaceuticals is www.eupraxiapharma.com

Which industry sector does Eupraxia Pharmaceuticals operate in?

Eupraxia Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SPRCSciSparc Ltd	US$ 0.7045 (218.49%)	93.96M
MGIHMillennium Group International Holdings Ltd	US$ 4.00 (161.44%)	23.72M
COEPCoeptis Therapeutics Holdings Inc	US$ 0.3188 (124.51%)	44.31M
ZCARZoomcar Holdings Inc	US$ 2.89 (102.10%)	18.98M
ADDColor Star Technology Company Ltd	US$ 4.12 (90.74%)	12.9M
BAOSBaosheng Media Group Holdings Ltd	US$ 4.8389 (-31.85%)	264.02k
NEUPNeuphoria Therapeutics Inc	US$ 4.59 (-30.77%)	118.34k
CREVCarbon Revolution Public Ltd	US$ 6.40 (-30.13%)	140.89k
HOURHour Loop Inc	US$ 3.09 (-29.77%)	611.72k
SVRESaverOne 2014 Ltd	US$ 1.07 (-29.14%)	425.28k
SPRCSciSparc Ltd	US$ 0.705 (218.72%)	93.96M
SMXSMX Security Matters Public Company	US$ 0.3789 (73.81%)	50.16M
COEPCoeptis Therapeutics Holdings Inc	US$ 0.3196 (125.07%)	44.33M
LICNLichen China Limited	US$ 0.2857 (35.98%)	27.18M
MGIHMillennium Group International Holdings Ltd	US$ 4.00 (161.44%)	23.72M